Clinical trials: Aggressive Behaviour
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort…
- Trial name
- NCT06806033
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Dating Violence, Dating Abuse
A Brief Intervention
This randomized controlled trial (RCT) study is a small scale test of the feasibility and preliminary efficacy of a brief motivational interview-style intervention.
- Trial name
- NCT01632176
- Testing
- Brief, motivational interview and one booster session
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Boston University
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
This phase Ib trial studies the side effects and best dose of DS3201 when given together with and ipilimumab for the treatment of patients with prostate, urothelial, or renal cell cancer that has spread to other places in the…
- Conditions
- Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04388852
- Testing
- Ipilimumab, Valemetostat
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
High-risk Aggressive Lymphoma After Auto-HSCT
Maintenance Therapy Post-HSCT in High-risk Aggressive Lymphoma
Relapse after autologous hematopoietic stem cell transplantation (ASCT) is still challenging for high-risk aggressive lymphoma. This study was to investigate the efficacy and safety of maintenance therapy post-ASCT.
- Trial name
- NCT03695055
- Testing
- Maintenance therapy post-HSCT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fujian Medical University
Childhood Trauma, Stress
Psychosocial Correlates of Trait Emotional Intelligence and Psychosomatic Symptoms Among Adolescents Exposed to Bullying and the Effects of Mindfulness-Based Stress Reduction.
This study examines the psychosocial correlates of trait emotional intelligence and psychosomatic symptoms among adolescents exposed to bullying and analyzes the effetiveness of Mindfulness Based Stress Reduction (MBSR) program…
- Conditions
- Childhood Trauma, Stress, Emotional Intelligence, Psychosomatic Disorders
- Trial name
- MBSR-RCT (NCT07694908)
- Testing
- Mindfulness Based Stress Reduction (MBSR)
- Where
- Pakistan
- Volunteers
- 44 people
- Sponsor
- Fatima Jinnah Women University
Malignant Lymphoma, Relapsed Non Hodgkin Lymphoma
Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT
In the study, we aimed to characterize the role of FDG PET/CT surveillance at 12 months of malignant lymphoma in asymptomatic patients after a first complete remission and to define a rational follow-up strategy.
- Conditions
- Malignant Lymphoma, Relapsed Non Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult, Diagnostic Imaging
- Trial name
- LYMPHOTEP1 (NCT04464590)
- Volunteers
- 100 people
- Sponsor
- University Hospital, Brest
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma
Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
This phase I/II trial is studying the side effects and best dose of oblimersen when given together with rituximab and combination chemotherapy and to see how well they work in treating patients with relapsed or refractory…
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
- Trial name
- NCT00086944
- Testing
- oblimersen sodium, rituximab, ifosfamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Burnout, Resilience
Burnout vs Resilience Among Healthcare Workers After the Recent Aggression in Lebanon
The purpose of this study is to assess the extent of burnout and the prevalence of resilience traits among healthcare workers in Lebanon, specifically after the recent Israeli aggression.
- Trial name
- NCT06974864
- Where
- Lebanon
- Volunteers
- 382 people, healthy volunteers welcome
- Sponsor
- Hopital Libanais Geitaoui
Non-Hodgkin's Lymphoma
Allo-hNHL (FluBuCy)
DSHNHL R3 is a randomized clinical phase II study. The main objective is to estimate the efficacy of rituximab as a prophylactic medication for prevention of graft-versus-host-disease after allogeneic peripheral stem cell…
- Trial name
- NCT00785330
- Testing
- standard GVHD prophylaxis, rituximab
- Where
- 6 sites in Germany
- Volunteers
- 84 people
- Sponsor
- Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Impulsive Aggression, ADHD
Dialectical Behavioral Therapy Skills for Impulsive Aggression
This trial aims to Study the efficacy of DBT skills for impulsive aggression and executive dysfunctions in drug naïve children who are presented with impulsive aggression and ADHD and attending Child and adolescent clinic at…
- Conditions
- Impulsive Aggression, ADHD, Executive Dysfunction
- Trial name
- NCT05351944
- Testing
- Dialectical behavioral therapy skills for the intervention experimental group A, psychoeducation or Atomoxetine or stimulants according to ADHD severity
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Alexandria University
Dementia, Pain
Preventing Aggression In Veterans With Dementia (PAVED) - Telephone Sub-Study With Rural Veterans
Aggression, a common symptom in persons with dementia, is linked with multiple treatable etiologies such as pain, depression, caregiver burden, and caregiver relationships.
- Trial name
- PAVED-T (NCT01385007)
- Testing
- Preventing Aggression in Veterans with Dementia (PAVeD)
- Volunteers
- 40 people
- Sponsor
- Michael E. DeBakey VA Medical Center
Pituitary Tumor
PITUItary Carcinoma or Aggressive Tumors REgistry -Lyon
The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity through computerized collection of comprehensive demographic, therapeutic, pathologic and outcome…
- Trial name
- PITUICARE-Lyon (NCT02854228)
- Where
- France
- Volunteers
- 1,300 people
- Sponsor
- Hospices Civils de Lyon
Oppositional Defiant Disorder
Treatment of Children With Peer Related Aggressive Behavior
The efficacy of the Treatment Program for Children with Aggressive Behaviour (Therapieprogramm für Kinder mit aggressivem Verhalten, THAV) which is a social competence training delivered in an individual format will be evaluated…
- Trial name
- NCT01406067
- Testing
- Treatment Program for Children with Aggressive Behavior, Play group
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University of Cologne
Periodontis, Aggressive Periodontitis
Single-cell and Spatial Transcriptomic Profiling of Gingival Tissues in Aggressive and Chronic Periodontitis: Deciphering Cellular Heterogeneity and Inflammatory Microenvironment Features
The goal of this observational study is to investigate cellular heterogeneity and inflammatory microenvironment features in gingival tissues from patients with aggressive periodontitis compared to chronic periodontitis and…
- Trial name
- NCT07487272
- Where
- China
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Alzheimer's Disease
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
The primary purpose of this study is to determine whether ELND005 is effective in treating symptoms of agitation and aggression in patients with Alzheimer's disease
- Trial name
- NCT01735630
- Testing
- ELND005
- Where
- 70 sites in United States, Canada and 2 more
- Volunteers
- 350 people
- Sponsor
- OPKO Health, Inc.
Alzheimer's Disease
Memantine on Aggression and Agitation of Alzheimer's Disease (AD)
Alzheimer's disease (AD), is associated with behavioral disturbances in approximately 50% of AD patients in Beijing. Agitation, and aggression specifically, is considered the most serious noncognitive symptom experienced in…
- Trial name
- NCT00703430
- Testing
- Memantine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University
Lymphoma
Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00290667
- Testing
- pegfilgrastim, rituximab, cyclophosphamide
- Where
- 338 sites in Czechia, France and 7 more
- Volunteers
- 586 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Lymphoma, B-cell Non-Hodgkin's Lymphoma
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
The purpose of this research is to study a treatment program for patients with aggressive lymphoma that has come back after initial or first therapy (called relapsed) or that has not responded to first therapy (called…
- Trial name
- NCT00588094
- Testing
- Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Autism Spectrum Disorder, Challenging Behaviour
Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism
The goal of this clinical trial is to learn if propranolol can help reduce challenging behaviors associated with Autism Spectrum Disorder, including aggression, self-injury, and severe disruptive behaviors.
- Conditions
- Autism Spectrum Disorder, Challenging Behaviour, Aggression, Severe Disruptive Behaviour Disorders
- Trial name
- NCT07091279
- Testing
- Propranolol
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Jeremy Veenstra-vanderweele
High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and…
- Conditions
- High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT06649812
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 114 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)